(Bloomberg) — A biotech stock focused on herbal medicine has surged by more than 46,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. Most Read from BloombergAs Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceAs American Architects Gather in Boston, Retrofits Are All the RageThe unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth nearly $30 bi
